[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tianjin Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":545},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,45,73,106,132,159,181,206,230,256,275,298,318,341,362,382,401,422,439,455,477,495,518],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100638493","programmed-cell-death-ligand-1-petct-in-various-pd-l1-related-disease-patients-100638493",false,"NCT07618936","Programmed Cell Death Ligand 1 PET\u002FCT in Various PD-L1-Related Disease Patients","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled PD-L1 PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.","ALL","18 Years","80 Years",{"count":19,"type":20},500,"ESTIMATED","7 Days","OBSERVATIONAL","To evaluate the potential usefulness of 68Ga\u002F18F-PD-L1 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various PD-L1-related disease patients",[25,26,27,28],"PD-L1 Gene Mutation","PD-L1 Gene Amplification","PD-L1-related Disease","Positron Emission Tomography",[30,31,32],"PET\u002FCT","PD-L1","DMP10","RECRUITING","2026-05-24",{"date":36,"type":37},"2026-06-01","ACTUAL",{"date":36,"type":20},{"date":40,"type":20},"2031-06-01",{"name":42,"class":43},"Tianjin Medical University","OTHER",2,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100638508","snrk--vascular-endothelial-aging-100638508","NCT07591337","SNRK & Vascular Endothelial Aging","The Association Between SNRK and Vascular Endothelial Aging","Inclusion Criteria:\n\n1. Aged 18-80 years, with the capacity to make decisions independently or represented by an authorized legal guardian;\n2. Able to provide complete personal information, medical history, and lifestyle history (e.g., smoking and alcohol consumption history);\n3. No history of severe cardiovascular disease, and deemed eligible for inclusion by a physician.\n\nExclusion Criteria:\n\n1. Women who are pregnant or may become pregnant;\n2. Patients with a history of neurological disorders, tumors, severe cardiovascular or pulmonary disease, liver failure, kidney failure, or blood disorders;\n3. Patients who have undergone carotid stenting, carotid endarterectomy, or other similar procedures, or who have unilateral carotid artery occlusion due to any cause;\n4. Patients who have participated in another clinical trial within the past 4 weeks;\n5. Individuals deemed unsuitable for this clinical trial by the investigators.",true,{"count":54,"type":20},180,"Cardiovascular diseases pose a serious threat to public health, and their prevalence is on the rise year by year. Vascular aging is an independent risk factor for cardiovascular diseases, and endothelial cell senescence is an early event in vascular aging. Its occurrence can lead to endothelium-dependent vasodilation dysfunction, reduced vascular permeability, and the release of the senescence-associated secretory phenotype (SASP). These vascular pathological changes further damage the vascular media, leading to vascular remodeling and reduced compliance, accelerating the progression of atherosclerosis, and ultimately resulting in cardiovascular diseases such as coronary heart disease and hypertension. Recent research of the investigators has revealed that SNRK, a new member of the AMPK family of cellular energy sensors, plays a key regulatory role in vascular development. Based on this finding, the investigators propose the scientific hypothesis that SNRK responds to both physiological and pathological aging stimuli through differential mechanisms and regulates the process of endothelial cell senescence. In this study, the investigators will explore the correlation between SNRKAS and carotid vascular structure and endothelial function by measuring the levels of the SNRK upstream lncRNA (SNRKAS) in participants' peripheral blood, in conjunction with carotid ultrasound examinations. The findings will provide a solid scientific basis for elucidating new mechanisms underlying the onset and progression of vascular aging and for identifying novel therapeutic targets.",[57],"Vascular Aging",[59,60,61,62,63],"SNRK","carotid atherosclerosis","vascular endothelial cells","cell senescence","vascular aging","2026-05-12",{"date":66,"type":37},"2026-05-15",{"date":68,"type":37},"2026-05-01",{"date":70,"type":20},"2029-04-30",{"name":42,"class":43},1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":72},"100630297","phase-4-fuke-qianjin-capsule-plus-antibiotics-for-chronic-endometritis-100630297","NCT07485842","FuKe Qianjin Capsule Plus Antibiotics for Chronic Endometritis","Randomized, Double-Blind, Single-Simulation, Multicenter Clinical Study Evaluating the Efficacy and Safety of FuKe Qianjin Capsules in Combination With Antibiotics for the Treatment of Chronic Endometritis.","FKQJCE","Inclusion Criteria:\n\n1. Age range: 20 years old ≤ age ≤ 40 years old;\n2. Meets the diagnostic criteria for chronic endometritis;\n3. Meets the Traditional Chinese Medicine(TCM) syndrome differentiation criteria for damp-heat with deficiency of both qi and blood;\n4. Has a regular menstrual cycle, with a cycle length ≥21 days and ≤35 days;\n5. Voluntarily participates and signs the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with concurrent acute genital tract and pelvic infections, etc.\n2. Patients with endometrial tuberculosis, endometrial cancer, or other malignant gynecological tumors.\n3. Patients with endometrial lesions, such as endometrial hyperplasia, uterine cavity adhesions, submucosal fibroids, or endometrial polyps.\n4. Patients with hydrosalpinx or pelvic abscesses.\n5. Patients with severe abnormalities in heart, liver, or kidney function.\n6. Patients with uncontrolled autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis, etc.).\n7. Patients with uncontrolled endocrine or metabolic diseases (e.g., diabetes, hyperthyroidism, or hypothyroidism, etc.).\n8. Patients with mental disorders (e.g., severe depression, schizophrenia) or unable to comply with follow-up.\n9. Pregnant or breastfeeding women, or those refusing contraception during treatment.\n10. Patients with allergies to study drugs (including Chinese herbal components or antibiotics).\n11. Patients who have participated in other clinical trials within the past 3 months.\n12. Other situations where the investigator deems the patient unsuitable for participation in the study.","FEMALE","20 Years","40 Years",{"count":85,"type":20},300,"INTERVENTIONAL",[88],"PHASE4","This randomized, double-blind, single-dummy, multicenter clinical study, led by Principal Investigator Xue Fengxia at Tianjin Medical University General Hospital (sponsor and primary trial institution) and funded by Zhuzhou Qianjin Pharmaceutical Co., Ltd., evaluates the safety and efficacy of FuKe Qianjin Capsules combined with standard antibiotic therapy for chronic endometritis (CE) in women aged 20-40 years. CE, a common gynecological inflammation marked by uterine plasma cell infiltration from bacterial infection, is linked to infertility, repeated implantation failure (RIF), and recurrent miscarriage (RM); it is often underdiagnosed due to non-specific symptoms, and first-line doxycycline therapy is limited by antibiotic resistance and high recurrence. FuKe Qianjin Capsules, a nationally recognized Chinese herbal medicine for gynecological inflammations, align with traditional Chinese medicine (TCM) treatment principles for CE (damp-heat stasis with qi and blood deficiency) and reduce antibiotic resistance per domestic research.\n\nApproximately 300 eligible participants (confirmed CE via hysteroscopy\u002Fpathology, matching TCM syndrome, regular menstrual cycles, informed consent) will be enrolled across 10-15 Chinese centers, with exclusion for acute infections, gynecological malignancies\u002F severe uterine lesions, organ dysfunction, uncontrolled systemic diseases, pregnancy\u002Flactation, drug hypersensitivity, or recent trial participation. All receive 14 days of oral doxycycline (100mg twice daily) and are randomized 1:1 to two double-blind groups (150 each): Experimental Group (56 days of FuKe Qianjin Capsules, 0.4g\u002Fcapsule, 2 capsules three times daily) or Control Group (56 days of matched capsule placebo).\n\nThe study includes a 28-day screening period, 56-day treatment phase, and 6-month post-treatment follow-up (in-person visits at Day 28±5\u002F56±7; telephone\u002Foutpatient follow-up at 3\u002F6 months). Efficacy assessments (hysteroscopy, TCM scoring, ultrasound), safety monitoring (vital signs, blood work, pregnancy testing), adverse event recording, and medication adherence checks occur at all visits, with ultrasound-confirmed clinical pregnancy rate as the key post-treatment outcome.\n\nThe team monitors known drug adverse effects (mild gastrointestinal\u002Fskin\u002Fneurological symptoms for the capsules; gastrointestinal\u002Fphotosensitivity\u002Frare liver\u002Fblood issues for doxycycline) and hysteroscopy risks (mild bleeding, rare perforation), with emergency protocols in place. Participants may withdraw voluntarily at any time with no impact on regular care; all data\u002Fspecimens are confidential, de-identified, and used only for study research (no commercial use).\n\nOverseen by the hospital's Institutional Ethics Committee and compliant with national research standards, the study's primary goal is to confirm the combined regimen's superior safety and efficacy over antibiotic monotherapy for CE, as well as its ability to improve reproductive outcomes and reduce recurrence. A positive result will establish this integrated Chinese-Western medicine approach as an evidence-based CE treatment, reducing antibiotic resistance and enhancing reproductive health for affected women, especially those with infertility, RIF, or recurrent miscarriage.",[91],"Chronic Endometritis",[91,93,94,95,96],"Clinical efficacy and safety","Combination Drug Therapy","Multicenter Clinical Studies","Fuke Qianjin Capsule","NOT_YET_RECRUITING","2026-03-17",{"date":100,"type":37},"2026-03-20",{"date":102,"type":20},"2026-04",{"date":104,"type":20},"2027-12",{"name":42,"class":43},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":72},"100564388","ali--pulmonary-ha-deposition-after-sah-100564388","NCT06628531","ALI & Pulmonary HA Deposition After SAH","Relationship Between Acute Lung Injury and Pulmonary Hyaluronic Acid Deposition After Subarachnoid Hemorrhage","Inclusion Criteria:\n\n* Age between 18 and 80 years old with independent behavior ability or authorized legal representative.\n* A documented diagnosis of SAH within 5 days.\n* A Hunt-Hess scale of Ⅳ or Ⅴ.\n* Absence of clinical and etiological evidence of pulmonary infection.\n\nExclusion Criteria:\n\n* Pregnant or lactating women.\n* Present history of traumatic brain injury or intracranial hemorrhage.\n* Past history of neurological disorders, lung infection within the past six months, cancer, chronic cardiopulmonary diseases, hematological diseases or renal failure.\n* Have participated in clinical trials in the past 4 weeks.\n* The investigator considers that not appropriate for inclusion.",{"count":114,"type":20},24,"Acute lung injury is a common complication of subarachnoid hematoma (SAH), and a significant risk factor for death in patients with SAH. Unlike neurogenic pulmonary edema and pneumonia following brain injury, the clinical causes of pulmonary injury after SAH are not intracranial hypertension or pulmonary infection. Its occurrence is influenced by the release of catecholamines, the regulatory function of the hypothalamic-pituitary-adrenal (HPA) axis and systemic inflammatory response, but the specific mechanisms are still unclear. Therefore, delving into the pathological mechanisms of SAH-induced lung injury and developing therapeutic strategies based on the findings is of great importance to improve the prognosis of patients.\n\nAbnormal accumulation of hyaluronic acid in the lungs has been reported to be closely related to the pathological progression of various pulmonary injury diseases, such as chest trauma, pulmonary infection and chronic obstructive pulmonary disease. From this, the present research is aimed to explore the levels and dynamic changes of hyaluronic acid in the bronchoalveolar lavage fluid and blood of patients with acute lung injury following SAH, and to analyze its correlation with the prognosis of pulmonary complications, thereby providing assistance for the clinical diagnosis and treatment of SAH.",[117],"Subarachnoid Haemorrhage (SAH)",[119,120,121,122,123],"Subarachnoid haemorrhage","SAH","acute lung injury","ALI","hyaluronic acid","2026-03-16",{"date":126,"type":37},"2026-03-18",{"date":128,"type":37},"2024-12-01",{"date":130,"type":20},"2026-09-30",{"name":42,"class":43},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":15,"minAge":139,"maxAge":4,"enrollmentInfo":140,"targetDuration":141,"studyType":22,"phases":4,"briefSummary":142,"conditions":143,"keywords":147,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":72},"100623211","effectiveness-of-xuanfei-jiangzhuo-decoction-for-influenza-induced-aecopd-100623211","NCT07393685","Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD","Effect of Xuanfei Jiangzhuo Decoction on Clinical Remission in Influenza-Induced AECOPD: Study Protocol for a Prospective, Real-World Cohort Study","Inclusion Criteria:\n\n* Diagnosed with Influenza-induced AECOPD according to the Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (GOLD 2025) and the Expert Consensus on the Diagnosis and Treatment of AECOPD in China (Updated 2023), confirmed by spirometry and viral testing (antigen or PCR), and excluding pneumonia and heart failure via chest CT and NT-proBNP.\n* Aged 60 years or older.\n* Voluntarily participate and provide written informed consent..\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to any component of the study medications.\n* Presence of severe bacterial co-infection at enrollment requiring systemic antibiotic therapy.\n* Severe dysfunction of major organs that may interfere with efficacy or safety assessment (e.g., severe cardiac insufficiency, hepatic impairment, or renal failure).\n* Participation in other interventional clinical trials within the past 3 months.\n* Inability to be contacted for follow-up (e.g., lack of permanent address or valid contact information).\n* Any other condition that, in the opinion of the investigator, would make the patient unsuitable for study participation (e.g., severe cognitive impairment or psychiatric disorders).","60 Years",{"count":85,"type":20},"28 Days","The goal of this observational study is to learn if a traditional Chinese herbal medicine (Xuanfei Jiangzhuo Decoction) works to help older adults recover from a COPD flare-up caused by the flu (influenza virus). The main questions it aims to answer are:\n\nDoes the herbal medicine help participants feel better and recover faster? Does it lower the chance of getting a second infection from bacteria? Is the herbal medicine safe to use? Researchers will compare participants who choose to take the herbal medicine along with their standard flu treatment (Oseltamivir or Baloxavir) to participants who only take the standard flu treatment (Oseltamivir or Baloxavir).\n\nParticipants will:\n\nTake the herbal medicine (a liquid drink) twice a day for 5 days, or just take their standard flu medicine for 5 days.\n\nVisit the clinic 4 times over 28 days for checkups and tests. Provide blood and stool samples to help researchers understand how the medicine affects the body and gut health.\n\nAnswer simple questions about their cough, breathing, and energy levels.",[144,145,146],"Acute Exacerbation of Chronic Obstructive Pulmonary Disease","Influenza, Human","Virus Diseases",[148,149,150],"COPD Exacerbation","Real-World Study","Traditional Chinese Medicine","2026-03-09",{"date":153,"type":37},"2026-03-12",{"date":155,"type":20},"2026-08-01",{"date":157,"type":20},"2028-05-31",{"name":42,"class":43},{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":52,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":165,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":166,"conditions":167,"keywords":171,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":44},"100589073","alpha-synuclein-petct-in-various--syn-related-disease-100589073","NCT06949670","Alpha-Synuclein PET\u002FCT in Various α-Syn-Related Disease","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated PD (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled α-Syn PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with none PD syndrome; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",{"count":19,"type":20},"To evaluate the potential usefulness of 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various α-Syn-related disease patients.",[168,169,170],"Alpha Synuclein Pathology","Alpha-Synuclein","Parkinson Disease",[30,172,169],"MRI","2026-01-27",{"date":175,"type":37},"2026-01-29",{"date":177,"type":37},"2025-04-01",{"date":179,"type":20},"2028-04-01",{"name":42,"class":43},{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":52,"sex":15,"minAge":16,"maxAge":187,"enrollmentInfo":188,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":189,"conditions":190,"keywords":194,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":44},"100622118","amino-acid-transporter-system-petct-imaging-in-aats-related-diseases-100622118","NCT07379463","Amino Acid Transporter System PET\u002FCT Imaging in AATS-Related Diseases","Inclusion Criteria:\n\n1. adult patients (aged 18 years or order);\n2. patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report);\n3. patients who had scheduled AATS PET\u002FCT scan;\n4. patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n1. patients with non-malignant lesions;\n2. patients with pregnancy;\n3. the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.","90 Years",{"count":19,"type":20},"To evaluate the potential usefulness of 11C\u002F18F-MET\u002FFET positron emission tomography\u002F computed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various amino acid transporter system (AATS)-related disease patients.",[191,192,193],"Amino-Acid Transport Disorder","Primary Hyperparathyroidism","Glioma",[30,195,196,197],"Amino acid transporter","MET","FET","2026-01-23",{"date":200,"type":37},"2026-01-30",{"date":202,"type":37},"2013-08-29",{"date":204,"type":20},"2033-08-29",{"name":42,"class":43},{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":52,"sex":15,"minAge":16,"maxAge":187,"enrollmentInfo":212,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":214,"conditions":215,"keywords":219,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":44},"100616514","18fnidf-pet-imaging-in-tau-related-diseases-100616514","NCT07306598","[18F]NIDF PET Imaging in Tau-related Diseases","Inclusion Criteria:\n\n1. Between 18 and 90 years old;\n2. No gender limitation;\n3. Clinical diagnositic rerults supported the diagnosis of neurodegeneration, and there was no evidence of other neurological diseases;\n4. Healthy participants or patients with probable Alzheimer's disease or with dementia due to other causes;\n5. Informed consent signed in person by the subject or his legal guardian or caregiver.\n\nExclusion Criteria:\n\n1. Has allergy to \\[18F\\]NIDF or any of its excipients;\n2. Incapable of providing written informed consent or lacking a legally authorized representative (LAR) to provide informed consent ;\n3. Unwilling or unable to undergo PET scans tracer injections;\n4. Any condition that, in the Investigator's opinion, could increase the risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection\u002Fanalysis of the data (e.g., renal or liver failure, advanced cancer);\n5. Received an experimental drug or device within 1 month (whose efficacy or safety is unclear);\n6. Have other serious neurological disorders, or gastrointestinal, cardiovascular, liver, kidney, blood system, tumor, endocrine, respiratory, immune deficiency, and other serious diseases;\n7. Women who are currently pregnant or breastfeeding.",{"count":213,"type":20},20,"In the field of diagnosing brain neurodegenerative diseases, it is now a well-established practice to inject positron-emitting tracers into the human body. These tracers bind to specific target proteins, allowing their distribution to be visualized via PET imaging. Currently, several research groups worldwide are engaged in developing and clinically validating their own tau imaging agents.\n\nThis clinical research project aims to visualize abnormal tau pathology in the living human brain using \\[18F\\]NIDF PET imaging. \\[18F\\]NIDF is a 2-arene-azaindole-based tracer that offers stronger binding affinity to tau neurofibrillary tangles and reduced non-specific\u002Foff-target binding compared to existing tau-PET imaging agents. The study primarily focuses on evaluating the safety and diagnostic efficacy of \\[18F\\]NIDF PET imaging in human subjects.",[216,217,218],"Neurodegenerative Disease","Alzheimer s Disease","Tauopathies",[30,220,221,218],"Alzheimer's disease","Tau pathologies","2025-12-14",{"date":224,"type":37},"2025-12-29",{"date":226,"type":37},"2025-11-01",{"date":228,"type":20},"2030-12-01",{"name":42,"class":43},{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":52,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":237,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":239,"conditions":240,"keywords":245,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":44},"100610813","18fft8-pet-imaging-in-immunoglobulin-light-chain-amyloidosis-100610813","NCT07232459","[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis","Clinical Study of [18F]FT8 PET\u002FCT in Evaluating Amyloidosis","1. Subject Recruitment Participants will be recruited from outpatients and\u002For inpatient populations of the Hematology Department at Tianjin Medical University General Hospital. The principal investigator and collaborating hematologists will ensure consistent application of diagnosis and enrollment criteria based on standardized guidelines. The planned enrollment includes 20 patients with systemic amyloidosis (including cardiac involvement) and 5 healthy volunteers.\n2. Amyloidosis Patients:\n\n2.1 Inclusion Criteria:\n\nSubjects must meet all of the following criteria:\n\n1. Adult patients (age ≥ 18 years);\n2. Suspected, newly diagnosed, or previously diagnosed with cardiac amyloidosis, with supporting evidence from one or more of the following: cardiac MRI, contrast-enhanced CT, serum biomarkers (e.g., NT-proBNP, Troponin), or histopathological confirmation of amyloidosis.\n3. Scheduled to undergo a clinical Pan-Amyloid PET\u002FCT scan as part of standard care or clinical evaluation.\n4. Able to understand the study procedures and provide written informed consent. 2.2 Exclusion Criteria\n\nSubjects will be excluded based on any of the following:\n\n1. Confirmed non-cardiac amyloidosis or other non-amyloid cardiac pathologies that could confound image interpretation.\n2. Pregnancy or breastfeeding.\n3. Any medical, psychological, or social condition that, in the opinion of the investigator, would compromise the subject's ability to participate fully or complete the study follow-up.\n\n3\\. Healthy Volunteers: 3.1 Inclusion Criteria:\n\nSubjects must meet all of the following criteria:\n\n1. Adult subjects (age ≥ 18 years);\n2. No clinical evidence of active cardiac or systemic disease, as confirmed by medical history review, physical examination, and electrocardiogram (ECG).\n3. Able to understand the study procedures and provide written informed consent. 3.2 Exclusion Criteria:\n\nSubjects will be excluded based on any of the following:\n\n1. History or current diagnosis of any significant cardiac, hepatic, renal, or neurological disorder.\n2. Pregnancy or breastfeeding.\n3. Any condition that, in the opinion of the investigator, could pose an increased risk from the study procedure or interfere with the interpretation of study data.",{"count":238,"type":20},25,"\\[18F\\]FT8, a derivative of 1-(4-pyridyl)-4-piperazinyl arene (\\[18F\\]TPZA), exhibits high affinity for AL amyloid in myocardial tissue sections and shows no significant binding to transthyretin amyloid. By comparing its diagnostic performance against established clinical methods, including echocardiography, contrast-enhanced MRI, and relevant laboratory tests, this study aims to establish \\[18F\\]FT8 as the basis for a robust PET protocol for the direct visualization and differential diagnosis of AL amyloidosis . The study preimarily evaluates the safety and diagnostic efficacy of \\[18F\\]FT8 PET imaging in human subjects.",[241,242,243,244],"Amyloid","Cardiac Amyloidosis","Amyloidosis","Healthy Subjects",[30,246,247],"Cardiac amyloidosis","immunoglobulin light chain","2025-11-15",{"date":250,"type":37},"2025-11-18",{"date":252,"type":37},"2025-07-21",{"date":254,"type":20},"2028-12-20",{"name":42,"class":43},{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":52,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":262,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":263,"conditions":264,"keywords":265,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":44},"100602980","pan-amyloid-petct-in-various-amyloid-related-disease-100602980","NCT07130565","Pan-Amyloid PET\u002FCT in Various Amyloid-Related Disease","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated cardiac amyloidosis (supporting evidence may include MRI, CT, serum markers and pathology report); (iii) patients who had scheduled Pan-Amyloid PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-CA lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",{"count":19,"type":20},"To evaluate the potential usefulness of 18F-92\u002FAV45\u002FTPZA\u002FFT8, 11C-PIB positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various Pan-Amyloid-related disease patients.",[241,242,243],[30,172,266],"Pan-Amyloid","2025-08-12",{"date":269,"type":37},"2025-08-19",{"date":271,"type":37},"2023-11-01",{"date":273,"type":20},"2028-11-01",{"name":42,"class":43},{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":52,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":281,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":282,"conditions":283,"keywords":288,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":44},"100569186","prostate-specific-membrane-antigen-petct-imaging-in-psma-related-disease-patients-100569186","NCT06690970","Prostate Specific Membrane Antigen PET\u002FCT Imaging in PSMA-Related Disease Patients","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled PSMA PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",{"count":19,"type":20},"To evaluate the potential usefulness of 68Ga\u002F18F-PSMA\u002FPSFA positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various PSMA-related disease patients.",[284,285,28,286,287],"PSMA-related Disease","Prostate Cancer","Metastasis","FAP",[30,289,287],"PSMA","2025-08-07",{"date":292,"type":37},"2025-08-11",{"date":294,"type":37},"2020-09-01",{"date":296,"type":20},"2027-12-01",{"name":42,"class":43},{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":52,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":304,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":305,"conditions":306,"keywords":309,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":316,"locationsCount":317},"100571857","beta-amyloid-petct-in-various-a-related-disease-100571857","NCT06725706","Beta Amyloid PET\u002FCT in Various Aβ-Related Disease","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Aβ PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",{"count":19,"type":20},"To evaluate the potential usefulness of 18F-92\u002FAV45, 11C-PIB positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.",[241,307,308],"Beta-Amyloid","Neurodegenerative Diseases",[30,172,307],"2025-06-03",{"date":312,"type":37},"2025-06-04",{"date":314,"type":37},"2012-09-01",{"date":296,"type":20},{"name":42,"class":43},3,{"id":319,"slug":320,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":52,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":325,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":326,"conditions":327,"keywords":331,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":72},"100589251","hydroxyephedrine-petct-in-sympathetic-nervous-system-disease-100589251","NCT06951984","Hydroxyephedrine PET\u002FCT in Sympathetic Nervous System Disease","Hydroxyephedrine PET\u002FCT in Sympathetic Nervous System Diseases","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled HED PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",{"count":19,"type":20},"To evaluate the potential usefulness of 11C\u002F18F-HED positron emission tomography\u002F computed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.",[328,329,330],"Sympathetic Nervous System Diseases","Sympathetic Nervous Structure Injury","Sympathetic Nerve Injury",[30,172,332],"Hydroxyephedrine","2025-04-23",{"date":335,"type":37},"2025-04-30",{"date":337,"type":37},"2013-03-01",{"date":339,"type":20},"2028-03-01",{"name":42,"class":43},{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":52,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":347,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":349,"conditions":350,"keywords":353,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":361,"locationsCount":44},"100571858","translocator-protein-petct-in-various-tspo-related-disease-100571858","NCT06725719","Translocator Protein PET\u002FCT in Various TSPO-Related Disease","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled TSPO PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",{"count":348,"type":20},200,"To evaluate the potential usefulness of 18F-DPA714\u002FFDPA positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various TSPO-related disease patients.",[351,352,308],"Neuroinflammation","Stroke",[30,172,354],"TSPO","2025-02-07",{"date":357,"type":37},"2025-02-11",{"date":359,"type":37},"2018-11-01",{"date":296,"type":20},{"name":42,"class":43},{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":52,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":368,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":369,"conditions":370,"keywords":374,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":376,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":72},"100571856","glucagon-like-peptide-1-receptor-petct-in-glp-1r-related-disease-100571856","NCT06725693","Glucagon-like Peptide-1 Receptor PET\u002FCT in GLP-1R Related Disease","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Exendin 4 PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",{"count":19,"type":20},"To evaluate the potential usefulness of 68Ga\u002F18F-Exendin 4 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various GLP-1R-related disease patients.",[371,372,373,28],"GLP1-R-related Disease","Tumor","Insulinoma",[30,375],"GLP1-R",{"date":357,"type":37},{"date":378,"type":37},"2019-02-01",{"date":380,"type":20},"2027-11-01",{"name":42,"class":43},{"id":383,"slug":384,"hasResults":11,"nctId":385,"briefTitle":386,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":52,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":388,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":389,"conditions":390,"keywords":392,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":396,"startDateStruct":397,"completionDateStruct":398,"leadSponsor":400,"locationsCount":72},"100569185","somatostatin-receptor-petct-in-sstr-related-disease-patients-100569185","NCT06690957","Somatostatin Receptor PET\u002FCT in SSTR-Related Disease Patients","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled SSTR PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",{"count":19,"type":20},"To evaluate the potential usefulness of 68Ga\u002F18F-TATE\u002FJR11\u002FLM3 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various SSTR-related disease patients.",[391,372,28,286],"SSTR-related Disease",[30,393,394,395],"SSTR","Angonist","Antagonist",{"date":357,"type":37},{"date":378,"type":37},{"date":399,"type":20},"2027-10-01",{"name":42,"class":43},{"id":402,"slug":403,"hasResults":11,"nctId":404,"briefTitle":405,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":52,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":407,"targetDuration":4,"studyType":86,"phases":408,"briefSummary":410,"conditions":411,"keywords":413,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":417,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":421,"locationsCount":72},"100569168","chemokine-receptor-4-petct-imaging-of-cxcr4-related-diseases-100569168","NCT06690736","Chemokine Receptor 4 PET\u002FCT Imaging of CXCR4-Related Diseases","Inclusion Criteria:\n\n* suspected or confirmed untreated Lymphoproliferative and other CXCR4-related diseases patients\n* 18F-FDG PET\u002FCT within two weeks\n* signed written consent.\n\nExclusion Criteria:\n\n* pregnancy\n* breastfeeding\n* known allergy against Pentixafor",{"count":348,"type":20},[409],"NA","To evaluate the potential usefulness of 68Ga\u002F18F-Pentixafor\u002FPentixather positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various CXCR4-related disease patients.",[412,372,28,286],"CXCR4-related Disease",[30,414,415,416],"Chemokine receptor 4","Pentixafor","Pentixather",{"date":357,"type":37},{"date":419,"type":37},"2022-03-01",{"date":399,"type":20},{"name":42,"class":43},{"id":423,"slug":424,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":52,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":428,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":429,"conditions":430,"keywords":432,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":434,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":438,"locationsCount":44},"100569187","tau-petct-in-various-tau-related-disease-patients-100569187","NCT06690983","Tau PET\u002FCT in Various Tau-Related Disease Patients","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Tau PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",{"count":19,"type":20},"To evaluate the potential usefulness of 18F-S16\u002FT807 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.",[218,308,431],"Neurodegeneration",[30,172,433],"Tau",{"date":357,"type":37},{"date":436,"type":37},"2018-08-01",{"date":296,"type":20},{"name":42,"class":43},{"id":440,"slug":441,"hasResults":11,"nctId":442,"briefTitle":443,"officialTitle":443,"acronym":4,"eligibilityCriteria":444,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":445,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":446,"conditions":447,"keywords":449,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":451,"startDateStruct":452,"completionDateStruct":453,"leadSponsor":454,"locationsCount":72},"100568963","fapi-petct-in-various-fap-related-disease-patients-100568963","NCT06688071","FAPI PET\u002FCT in Various FAP-Related Disease Patients","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled FAPI PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",{"count":19,"type":20},"To evaluate the potential usefulness of 68Ga\u002F18F-FAPI positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various FAP-related disease patients.",[448,372,28,286],"FAP-related Disease",[30,287,450],"FAPI",{"date":357,"type":37},{"date":419,"type":37},{"date":399,"type":20},{"name":42,"class":43},{"id":456,"slug":457,"hasResults":11,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":462,"enrollmentInfo":463,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":465,"conditions":466,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":72},"100484796","a-study-of-yutiq-018-mg-intravitreal-implant-for-the-management-of-chronic-non-infectious-uveitis-100484796","NCT05592717","A Study of YUTIQ® 0.18 mg Intravitreal Implant for the Management of Chronic Non-infectious Uveitis","An Observational Study of YUTIQ (Fluocinolone Acetonide Intravitreal Implant 0.18 mg) for the Management of Chronic Non-infectious Uveitis","Inclusion Criteria:\n\n1. Male or female in good general health at 18 to 70 years of age.\n2. Presence of unilateral or bilateral non-infectious uveitis affecting the posterior segment\n3. Patients have active inflammation before Yutiq treatment. Subject meets at least 1 of the following criteria: 1. ≥1+ anterior chamber cell and\u002For ≥1+ vitreous haze. 2. Fluorescein angiography demonstrates leakages. 3. OCT images showing the macular edema. 4. The times of relapse in one year are equal to or greater than 3.\n4. Steroids and immunosuppressive agents were discontinued within 3 months after Yutiq injection.\n\nExclusion Criteria:\n\n1. Subject with corneal or lens opacity that precludes visualization of the fundus or that likely requires cataract surgery during the duration of the trial.\n2. Subject with a history of neurologic symptoms suggestive of central nervous system demyelinating disease.\n3. Prior intravitreal treatment with Retisert®, ILUVIEN®, or YUTIQ® (0.18 mg) within 36 months prior to Day 1.\n4. Prior intravitreal treatment with OZURDEX® within 12 weeks prior to Day 1. Prior intravitreal treatment with Triesence® or TRIVARIS™ (triamcinolone) within 12 weeks prior to Day 1.\n5. Peri-ocular or subtenon steroid treatment within 12 weeks prior to Day 1.\n6. Media opacity precluding evaluation of retina and vitreous (eg, vitreous hemorrhage).\n7. Hypersensitivity to any of the ingredients contained in YUTIQ®.\n8. Any other systemic or ocular condition which, in the judgment of the Investigator, could make the subject inappropriate for study enrollment.\n9. Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method of contraception as outlined in the protocol from at least 14 days prior to Day 1 until the final study visit.","70 Years",{"count":464,"type":20},15,"This project is designed to evaluate the efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious uveitis.",[467,468],"Uveitis","YUTIQ","2024-07-01",{"date":471,"type":37},"2024-07-03",{"date":473,"type":37},"2023-01-05",{"date":475,"type":20},"2026-11-01",{"name":42,"class":43},{"id":478,"slug":479,"hasResults":11,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":4,"eligibilityCriteria":483,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":462,"enrollmentInfo":484,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":485,"conditions":486,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":489,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":72},"100484620","a-study-of-adalimumab-in-acute-vogt-koyanagi-harada-disease-100484620","NCT05590416","A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease","An Observational Study of Adalimumab in the Treatment of Acute Vogt-Koyanagi-Harada Disease","Inclusion Criteria:\n\n1. Subject is 18 to 70 years of age.\n2. Subjects who do not have previous, active or latent tuberculosis (TB).\n3. Subject must have Vogt-Koyanagi-Harada disease less than one month.\n4. Subject who were previously treated with systemic glucocorticoid less than one week.\n5. Subject meets at least 1 of the following criteria:\n\n1)patients who reject using systemic glucocorticoid because of the long-term side effects. 2)patients with other high-risk or systemic disease were limited by the use of glucocorticoid. 3)patients with a little reparation of retinal detachments after a week treatment with powerful systemic glucocorticoid(≥1mg\u002Fkg\u002Fday).\n\nExclusion Criteria:\n\n1. Subject with confirmed or suspected infectious uveitis, including but not limited to infectious uveitis due to TB, cytomegalovirus (CMV), Human T-Lymphotropic Virus Type 1 (HTLV-1), Whipple's disease, Herpes Zoster virus (HZV), Lyme disease, toxoplasmosis and herpes simplex virus (HSV).\n2. Subject with corneal or lens opacity that precludes visualization of the fundus or that likely requires cataract surgery during the duration of the trial.\n3. Subject has previous exposure to anti-tumor necrosis factor (TNF) therapy or any biologic therapy with a potential therapeutic impact on non-infectious uveitis.\n4. Subject has received Ozurdex® (dexamethasone implant) within 6 months prior to the Baseline visit.\n5. Subject has received intravitreal anti-VEGF therapy within 45 days of the Baseline visit for Lucentis® (ranibizumab) or Avastin® (bevacizumab) or within 60 days of the Baseline visit for anti-VEGF Trap (aflibercept).\n6. Subject has received intravitreal methotrexate within 90 days prior to the Baseline visit.",{"count":464,"type":20},"This project is designed to test the hypothesis that adalimumab is clinically useful for patients with acuta Vogt-Koyanagi-Harada disease",[487,488],"Vogt-Koyanagi-Harada Disease","Adalimumab",{"date":471,"type":37},{"date":491,"type":37},"2021-06-01",{"date":493,"type":20},"2024-12-30",{"name":42,"class":43},{"id":496,"slug":497,"hasResults":11,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":11,"sex":15,"minAge":502,"maxAge":17,"enrollmentInfo":503,"targetDuration":4,"studyType":86,"phases":504,"briefSummary":506,"conditions":507,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":72},"100509290","early-phase-1-clinical-study-of-high-concentration-ganciclovir-eye-drops-in-the-treatment-of-cytomegalovirus-retinitis-100509290","NCT05911503","Clinical Study of High Concentration Ganciclovir Eye Drops in the Treatment of Cytomegalovirus Retinitis","A Clinical Study of High Concentration(2%) Ganciclovir Eye Drops in the Treatment of Cytomegalovirus Retinitis","Inclusion Criteria:\n\n1. Patients voluntarily participate in studies and sign informed consent forms\n2. Ages 2-80 years (with cut-off values) male and female\n3. One of the following is true （1）In patients with cytomegalovirus retinitis after hematopoietic stem cell transplantation\u002Fcord blood transplantation, the white blood cell count is less than 4× 10\\^9\u002FL, and the platelet count ranges are 25× 10\\^9\u002FL≤ PLT\\\u003C100×10\\^9\u002FL，Intravitreal injection carries a greater risk of infection and bleeding, and is unable to administer systemic medication due to the bone marrow suppression of antiviral drugs, or systemic medication for severe CMV retinitis cannot be well controlled; （2）In patients with CMVR with AIDS, the CD4+ T cell count is less than 100\u002Fμl, there is a great risk of infection with intravitreal injection, and the systemic medication of severe CMV retinitis cannot be well controlled.\n\nExclusion Criteria:\n\n* Eye condition\n\n  1. The presence of refractive interstitial opacification affects fundus observation;\n  2. Intravitreal ganciclovir or sodium phosformate injections were performed within 1 week prior to baseline;\n  3. Other diseases that can affect visual function such as syphilis-related eye diseases, acute retinal necrosis, congenital glaucoma, congenital corneal lesions, congenital macular degeneration, etc.\n* General condition\n\n  1. Severe neutropenia (\\\u003C0.5×10\\^9) or severe thrombocytopenia (\\\u003C 25× 10\\^9\u002FL);\n  2. Other investigators judged patients who were not suitable for enrollment;","2 Years",{"count":464,"type":20},[505],"EARLY_PHASE1","Clinical study of high concentration ganciclovir eye drops in the treatment of cytomegalovirus retinitis",[508,509],"Cytomegalovirus Retinitis","Ganciclovir Eye Drops","2023-06-21",{"date":512,"type":37},"2023-06-23",{"date":514,"type":20},"2023-07-01",{"date":516,"type":20},"2027-06-30",{"name":42,"class":43},{"id":519,"slug":520,"hasResults":11,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":4,"eligibilityCriteria":524,"healthyVolunteers":52,"sex":81,"minAge":525,"maxAge":83,"enrollmentInfo":526,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":528,"conditions":529,"keywords":531,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":44},"100495408","displacement-of-iodine-balance-value-during-pregnancy-and-the-mechanism-of-breast-iodine-homeostasis-during-lactation-100495408","NCT05730803","Displacement of Iodine Balance Value During Pregnancy and the Mechanism of Breast Iodine Homeostasis During Lactation","Study on the Displacement of Iodine Balance Value During Pregnancy and the Mechanism of Breast Iodine Homeostasis During Lactation Under Different Iodine Exposure","Inclusion Criteria:\n\nPregnant women:\n\n* Aged 18-40, who have lived in the area for ≥5 year;\n* Single pregnancy;\n* Those who have no special dietary habits;\n\nLactating woman:\n\n* Breastfeeding a child;\n* Normal thyroid function during pregnancy;\n* Term delivery (38-42 weeks of gestation);\n\nExclusion Criteria:\n\nPregnant women:\n\n* Smoking or drinking;\n* Iodized drugs or contrast agents have been used in the past year;\n* A history of thyroid disease, autoimmune disease, endocrine disease, heart disease, chronic disease or family hereditary disease, etc\n\nLactating woman:\n\n* A history of thyroid disease, autoimmune disease, endocrine disease, heart disease, chronic disease or family hereditary disease, etc;\n* Iodized drugs or contrast agents have been used;","1 Day",{"count":527,"type":20},1200,"In order to solve the bottleneck problems of\"zero balance displacement\"and\"large variation of breastmilk\"in the study of iodine EAR of pregnant women, lactating women and infants, firstly, this study intends to clarify the rate of metabolism and distribution of iodine during pregnancy by 125I tracer, SPECT\u002FCT in vivo small animal imaging and γ counting study. Then, the iodine balance study in rats was conducted to verify the degree of \"zero balance value displacement\"caused by the difference of iodine absorption and store in different organs and tissues under different iodine exposure levels, so as to determine the iodine selection conditions of subjects in the population experiment. To determine the EAR of pregnant women by optimizing the population iodine balance experiment. Secondly, we proposed to study the regulatory mechanism of NIS and Pendrin in the mammary gland of lactating rats under different iodine nutrition levels to clarify the range of breastmilk iodine compensation. Mammary cell experiments intend to clarify the mutual regulations of iodine nutrition, oestrogen, and NIS and Pendrin. Based on the results of animal and cellular experiments, and the effect of genetic, oestrogen and iodine status were considered, a cross-sectional study of lactating women was conducted to determine the normal reference range of breastmilk iodine after screening out the people with abnormal indicators. This study will solve the bottleneck problems and difficulties in the iodine RNI research for pregnant women, lactating women and infants, found the iodine nutritional compensatory mechanism under special physiology, and provide the scientific basis for obtaining the accurate EAR basic data and the revision of iodine DRIs.",[530],"Nutritional Requirements",[532,533,534,535,536],"nutrition of special population","nutrient","trace element iodine","zero balance displacement","large variation of breastmilk","2023-02-15",{"date":539,"type":37},"2023-02-16",{"date":541,"type":20},"2023-02-17",{"date":543,"type":20},"2027-12-31",{"name":42,"class":43},""]